Get notified when MAIA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMAIA Biotechnology activates first U.S. site for Phase 2 lung cancer trial
Filed April 16, 2026 · Period ending April 16, 2026 · ~1 min read
Key Changes
-
high
Company opened its first U.S. clinical trial site for an ongoing international Phase 2 study testing a telomere-targeting therapy for advanced non-small cell lung cancer, expanding the trial's geographic reach into the American market.
Press Release, April 16, 2026 view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade MAIA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify